Kyowa Kirin Frontier

Kyowa Kirin Frontier Co., Ltd. is a wholly-owned subsidiary of Kyowa Kirin, established in 2023 and headquartered in Tokyo, Japan. The company was specifically formed to manage the authorized generic (AG) business and ensure a stable supply of high-quality pharmaceutical products within the Japanese market. Its portfolio includes authorized generic versions of Kyowa Kirin's core therapies, such as Darbepoetin Alfa for renal anemia, as well as long-listed products like Benidipine and Olopatadine. By leveraging the parent company's established manufacturing standards and R&D heritage, Kyowa Kirin Frontier provides cost-effective treatment options that maintain the reliability of original branded drugs. The company plays a vital role in Kyowa Kirin's broader strategy to optimize its product lifecycle and support the sustainability of the national healthcare system.